Early detection of ovarian cancer using group biomarkers

Alain B. Tchagang, Ahmed H. Tewfik, Melissa S. DeRycke, Keith M Skubitz, Amy P Skubitz

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

One reason that ovarian cancer is such a deadly disease is because it is not usually diagnosed until it has reached an advanced stage. In this study, we developed a novel algorithm for group biomarkers identification using gene expression data. Group biomarkers consist of coregulated genes across normal and different stage diseased tissues. Unlike prior sets of biomarkers identified by statistical methods, genes in group biomarkers are potentially involved in pathways related to different types of cancer development. They may serve as an alternative to the traditional single biomarkers or combination of biomarkers used for the diagnosis of early-stage and/or recurrent ovarian cancer. We extracted group biomarkers by applying biclustering algorithms that we recently developed on the gene expression data of over 400 normal, cancerous, and diseased tissues. We identified several groups of coregulated genes that encode for secreted proteins and exhibit expression levels in ovarian cancer that are at least 2-fold (in log2 scale) higher than in normal ovary and nonovarian tissues. In particular, three candidate group biomarkers exhibited a conserved biological pattern that may be used for early detection or recurrence of ovarian cancer with specificity greater than99%and sensitivity equal to 100%. We validated these group biomarkers using publicly available gene expression data sets downloaded from a NIH Web site (http://www.ncbi.nlm.nih.gov/geo). Statistical analysis showed that our methodology identified an optimum combination of genes that have the highest effect on the diagnosis of the disease compared with several computational techniques that we tested. Our study also suggests that single or group biomarkers correlate with the stage of the disease.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalMolecular Cancer Therapeutics
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Early Detection of Cancer
Ovarian Neoplasms
Biomarkers
Gene Expression
Genes
Social Identification
Ovary
Recurrence

Cite this

Early detection of ovarian cancer using group biomarkers. / Tchagang, Alain B.; Tewfik, Ahmed H.; DeRycke, Melissa S.; Skubitz, Keith M; Skubitz, Amy P.

In: Molecular Cancer Therapeutics, Vol. 7, No. 1, 01.01.2008, p. 27-37.

Research output: Contribution to journalArticle

Tchagang, Alain B. ; Tewfik, Ahmed H. ; DeRycke, Melissa S. ; Skubitz, Keith M ; Skubitz, Amy P. / Early detection of ovarian cancer using group biomarkers. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 1. pp. 27-37.
@article{b22a57286f1246c9890f879d38e6b489,
title = "Early detection of ovarian cancer using group biomarkers",
abstract = "One reason that ovarian cancer is such a deadly disease is because it is not usually diagnosed until it has reached an advanced stage. In this study, we developed a novel algorithm for group biomarkers identification using gene expression data. Group biomarkers consist of coregulated genes across normal and different stage diseased tissues. Unlike prior sets of biomarkers identified by statistical methods, genes in group biomarkers are potentially involved in pathways related to different types of cancer development. They may serve as an alternative to the traditional single biomarkers or combination of biomarkers used for the diagnosis of early-stage and/or recurrent ovarian cancer. We extracted group biomarkers by applying biclustering algorithms that we recently developed on the gene expression data of over 400 normal, cancerous, and diseased tissues. We identified several groups of coregulated genes that encode for secreted proteins and exhibit expression levels in ovarian cancer that are at least 2-fold (in log2 scale) higher than in normal ovary and nonovarian tissues. In particular, three candidate group biomarkers exhibited a conserved biological pattern that may be used for early detection or recurrence of ovarian cancer with specificity greater than99{\%}and sensitivity equal to 100{\%}. We validated these group biomarkers using publicly available gene expression data sets downloaded from a NIH Web site (http://www.ncbi.nlm.nih.gov/geo). Statistical analysis showed that our methodology identified an optimum combination of genes that have the highest effect on the diagnosis of the disease compared with several computational techniques that we tested. Our study also suggests that single or group biomarkers correlate with the stage of the disease.",
author = "Tchagang, {Alain B.} and Tewfik, {Ahmed H.} and DeRycke, {Melissa S.} and Skubitz, {Keith M} and Skubitz, {Amy P}",
year = "2008",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-07-0565",
language = "English (US)",
volume = "7",
pages = "27--37",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Early detection of ovarian cancer using group biomarkers

AU - Tchagang, Alain B.

AU - Tewfik, Ahmed H.

AU - DeRycke, Melissa S.

AU - Skubitz, Keith M

AU - Skubitz, Amy P

PY - 2008/1/1

Y1 - 2008/1/1

N2 - One reason that ovarian cancer is such a deadly disease is because it is not usually diagnosed until it has reached an advanced stage. In this study, we developed a novel algorithm for group biomarkers identification using gene expression data. Group biomarkers consist of coregulated genes across normal and different stage diseased tissues. Unlike prior sets of biomarkers identified by statistical methods, genes in group biomarkers are potentially involved in pathways related to different types of cancer development. They may serve as an alternative to the traditional single biomarkers or combination of biomarkers used for the diagnosis of early-stage and/or recurrent ovarian cancer. We extracted group biomarkers by applying biclustering algorithms that we recently developed on the gene expression data of over 400 normal, cancerous, and diseased tissues. We identified several groups of coregulated genes that encode for secreted proteins and exhibit expression levels in ovarian cancer that are at least 2-fold (in log2 scale) higher than in normal ovary and nonovarian tissues. In particular, three candidate group biomarkers exhibited a conserved biological pattern that may be used for early detection or recurrence of ovarian cancer with specificity greater than99%and sensitivity equal to 100%. We validated these group biomarkers using publicly available gene expression data sets downloaded from a NIH Web site (http://www.ncbi.nlm.nih.gov/geo). Statistical analysis showed that our methodology identified an optimum combination of genes that have the highest effect on the diagnosis of the disease compared with several computational techniques that we tested. Our study also suggests that single or group biomarkers correlate with the stage of the disease.

AB - One reason that ovarian cancer is such a deadly disease is because it is not usually diagnosed until it has reached an advanced stage. In this study, we developed a novel algorithm for group biomarkers identification using gene expression data. Group biomarkers consist of coregulated genes across normal and different stage diseased tissues. Unlike prior sets of biomarkers identified by statistical methods, genes in group biomarkers are potentially involved in pathways related to different types of cancer development. They may serve as an alternative to the traditional single biomarkers or combination of biomarkers used for the diagnosis of early-stage and/or recurrent ovarian cancer. We extracted group biomarkers by applying biclustering algorithms that we recently developed on the gene expression data of over 400 normal, cancerous, and diseased tissues. We identified several groups of coregulated genes that encode for secreted proteins and exhibit expression levels in ovarian cancer that are at least 2-fold (in log2 scale) higher than in normal ovary and nonovarian tissues. In particular, three candidate group biomarkers exhibited a conserved biological pattern that may be used for early detection or recurrence of ovarian cancer with specificity greater than99%and sensitivity equal to 100%. We validated these group biomarkers using publicly available gene expression data sets downloaded from a NIH Web site (http://www.ncbi.nlm.nih.gov/geo). Statistical analysis showed that our methodology identified an optimum combination of genes that have the highest effect on the diagnosis of the disease compared with several computational techniques that we tested. Our study also suggests that single or group biomarkers correlate with the stage of the disease.

UR - http://www.scopus.com/inward/record.url?scp=38349135710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349135710&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-0565

DO - 10.1158/1535-7163.MCT-07-0565

M3 - Article

C2 - 18187805

AN - SCOPUS:38349135710

VL - 7

SP - 27

EP - 37

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -